Health Protection Agency

Last updated

Health Protection Agency
Agency overview
Formed2004
Preceding agency
Dissolved2013
Superseding agency
Jurisdiction England
HeadquartersLondon SW1
Employees3,155 (2,831 at HPA and 324 NRPB)
Annual budget£244.7 million (2008–2009)
Minister responsible
Parent agency Department of Health
Website www.hpa.org.uk

The Health Protection Agency (HPA) was a non-departmental public body in the United Kingdom. [1] It was set up by the UK government in 2003 to protect the public from threats to their health from infectious diseases and environmental hazards. [2]

Contents

The HPA's role was to provide an integrated approach to protecting public health in the UK. It did this by providing advice and information to the general public, health professionals and local government, and by providing emergency services, support and advice to the National Health Service (NHS) and the Department of Health. The HPA also had a lead role in helping preparations for new and emerging health threats, such as a bioterrorism or emerging virulent disease strains.

There were four HPA centres – at Porton Down in Salisbury, Chilton in Oxfordshire, South Mimms in Hertfordshire, and Colindale in NW London. In addition, the HPA had regional laboratories across England and administrative headquarters in Central London. On 1 April 2013, the HPA minus the South Mimms site became part of Public Health England, a new executive agency of the Department of Health (DoH). The National Institute for Biological Standards and Control (NIBSC) located in South Mimms was merged with the Medicines and Healthcare products Regulatory Agency (MHRA).

History

The Health Protection Agency (HPA) was originally established as an NHS special health authority in 2003. On 1 April 2005, the Agency became a non-departmental public body, with the National Radiological Protection Board (NRPB) being merged into the organisation at the same time.

Main entrance of the HPA Colindale HQ HealthprotectionagencyHQ.jpg
Main entrance of the HPA Colindale HQ

The origins of the HPA's largest facility in Porton Down can be traced back to 1940, when Porton had a highly secret and independent 'Biology Department' under the Ministry of Defence to study biological warfare and defence against it. By 1946 it was called the 'Microbiological Research Department', and from 1951 the 'Microbiological Research Establishment', with research becoming increasingly defensive and civilian in nature. Total civilian control was established by moving biological defence work to the Chemical Defence Establishment (now dstl), and renaming the facility from 1 April 1979 as the Centre for Applied Microbiology and Research (CAMR) within the Public Health Laboratory Service (PHLS). In April 1994, CAMR moved from PHLS centre to the Microbiological Research Authority (MRA), reporting to the Department of Health and continuing the programme in civil microbiological research started in 1979.

Microbiology Services remained the biggest of the four Divisions within the HPA with 1800 staff, consisting of laboratory groups from the Centre for Emergency Preparedness and Response, the Centre for Infections, eight regional microbiology laboratories and 37 collaborating hospital laboratories. Together, these laboratories provided frontline diagnostic and public health microbiology services to NHS trusts and HPA health protection units. Its remit included infectious disease surveillance, providing specialist and reference microbiology and microbial epidemiology, coordinating the investigation and cause of national and uncommon outbreaks, helping advise government on the risks posed by various infections and responding to international health alerts. In addition, both basic and applied research was undertaken into understanding infectious diseases, and the group manufactured a number of healthcare products including vaccines and therapeutics. For instance, the HPA was the sole licensed manufacturer of anthrax vaccine in the UK. [3]

Funding

HPA was accountable to the UK Secretary of State for Health, and was funded primarily by Government Grant in Aid. Other income was received from the NHS, commercial activities, grants, and other sources. HPA’s income for the fiscal year ending 31 March 2008, was £160.2 million from Revenue Government financing plus £109.2 million total operating income. [4] Total average staff numbers for that year, including secondments and agency staff, were 3,394 staff.

Organisation

Following consultation during April 2010, the HPA was organised into four groups: Microbiology Services, Health Protection Services, Biological Standards and Control, and the Centre for Radiation, Chemical and Environmental Hazards.

Microbiology Services

The Division included laboratory groups from the Centre for Infections, Centre for Emergency Preparedness and Response, the Regional Microbiology Network and their associated supports. The remit of the Centre included infectious disease surveillance, providing specialist and reference microbiology and microbial epidemiology, coordinating the investigation and cause of national and uncommon outbreaks, helping advise government on the risks posed by various infections and responding to international health alerts.

The Centre for Emergency Preparedness and Response prepared for and coordinated responses to potential healthcare emergencies, including possible acts of deliberate release. In addition, both basic and applied research were undertaken into understanding infectious diseases and the Centre manufactured a number of healthcare products, including vaccines and therapeutics. Internationally recognised as a world leader in microbiology research and testing, HPA's Porton Down Centre worked with foreign governments, international biotechnology and pharmaceutical corporations, and start-up and spin-out companies. The strategic goal of the Centre was "to build on and develop the intellectual assets of the organisation in partnership with industry." Areas of expertise include: bacterial vaccines, toxin therapeutics, Good Laboratory Practice (GLP) and in-vivo testing of compounds, biodefence and biosafety testing, diagnostics, and the provision of cell cultures.

The Regional Microbiology Network was composed of eight regional microbiology laboratories. In addition, 37 hospital microbiology laboratories participated as HPA collaborating laboratories. Together, these laboratories provided frontline diagnostic and public health microbiology services to NHS trusts and HPA health protection units.

Health Protection Services

This Division comprised two nationally organised services, each with their own head: LaRS and a new National Epidemiology Service. Combining these services into one grouping was intended to facilitate and reinforce close team working among those with skills relevant to delivering effective and consistent responses to significant health protection threats. LaRS provided support to the front line response by coordinating services at the regional and local level. It was a source of specialist advice and operational support, and it contributed actively to policy making and implementation in partnership with other HPA divisions and with the NHS, local authorities and other agencies.

Centre for Radiation, Chemical and Environmental Hazards (CRCE)

The Centre for Radiation, Chemical and Environmental Hazards comprised the Radiation Protection Division (formerly the National Radiological Protection Board) and the Chemical Hazards and Poisons Division. The base for the Centre was in Chilton, Oxfordshire.

National Institute for Biological Standards and Control (NIBSC)

The National Institute for Biological Standards and Control's (NIBSC) mission was to assure the quality of biological medicines. At the heart of the work was the preparation, storage and worldwide distribution of World Health Organization international standards and reference materials to provide benchmarks for product quality. In addition NIBSC provided testing services as the UK's Official Medicines Control Laboratory to ensure compliance with product specifications. These activities and advice provided by NIBSC were underpinned by leading edge scientific research covering a wide range of scientific disciplines. In April 2013, the NIBSC left the HPA and was merged with the UK's Medicines and Healthcare products Regulatory Agency.

Health Protection Agency Annual Conference

The Health Protection Agency Annual Conference, which was attended by approximately one thousand health professionals and scientists to promote scientific excellence and best practice in health protection and emergency planning, brought together experts from a wide variety of disciplines to share knowledge of the latest scientific research and developments. The conference continued after 2013 as the "Public Health England Annual Conference".

See also

51°35′38″N0°15′14″W / 51.5940°N 0.2538°W / 51.5940; -0.2538

Related Research Articles

<span class="mw-page-title-main">Biosafety</span> Prevention of large-scale loss of biological integrity

Biosafety is the prevention of large-scale loss of biological integrity, focusing both on ecology and human health. These prevention mechanisms include the conduction of regular reviews of biosafety in laboratory settings, as well as strict guidelines to follow. Biosafety is used to protect from harmful incidents. Many laboratories handling biohazards employ an ongoing risk management assessment and enforcement process for biosafety. Failures to follow such protocols can lead to increased risk of exposure to biohazards or pathogens. Human error and poor technique contribute to unnecessary exposure and compromise the best safeguards set into place for protection.

Biodefense refers to measures to restore biosecurity to a group of organisms who are, or may be, subject to biological threats or infectious diseases. Biodefense is frequently discussed in the context of biowar or bioterrorism, and is generally considered a military or emergency response term.

<span class="mw-page-title-main">Biosafety level</span> Level of the biocontainment precautions required to isolate dangerous biological agents

A biosafety level (BSL), or pathogen/protection level, is a set of biocontainment precautions required to isolate dangerous biological agents in an enclosed laboratory facility. The levels of containment range from the lowest biosafety level 1 (BSL-1) to the highest at level 4 (BSL-4). In the United States, the Centers for Disease Control and Prevention (CDC) have specified these levels in a publication referred to as BMBL. In the European Union, the same biosafety levels are defined in a directive. In Canada the four levels are known as Containment Levels. Facilities with these designations are also sometimes given as P1 through P4, as in the term P3 laboratory.

<span class="mw-page-title-main">Biological hazard</span> Biological material that poses serious risks to the health of living organisms

A biological hazard, or biohazard, is a biological substance that poses a threat to the health of living organisms, primarily humans. This could include a sample of a microorganism, virus or toxin that can adversely affect human health. A biohazard could also be a substance harmful to other living beings.

Health Canada is the department of the Government of Canada responsible for national health policy. The department itself is also responsible for numerous federal health-related agencies, including the Canadian Food Inspection Agency (CFIA) and the Public Health Agency of Canada (PHAC), among others. These organizations help to ensure compliance with federal law in a variety of healthcare, agricultural, and pharmaceutical activities. This responsibility also involves extensive collaboration with various other federal- and provincial-level organizations in order to ensure the safety of food, health, and pharmaceutical products—including the regulation of health research and pharmaceutical manufacturing/testing facilities.

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care in the United Kingdom which is responsible for ensuring that medicines and medical devices work and are acceptably safe.

The National Microbiology Laboratory (NML) is part of the Public Health Agency of Canada (PHAC), the agency of the Government of Canada that is responsible for public health, health emergency preparedness and response, and infectious and chronic disease control and prevention.

<span class="mw-page-title-main">European Centre for Disease Prevention and Control</span> Agency of the European Union

The European Centre for Disease Prevention and Control (ECDC) is an agency of the European Union (EU) whose mission is to strengthen Europe's defences against infectious diseases. It covers a wide spectrum of activities, such as: surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance. The centre was established in 2004 and is headquartered in Solna, Sweden.

<span class="mw-page-title-main">Biocontainment</span> Physical containment of pathogenic organisms or agents in microbiology laboratories

One use of the concept of biocontainment is related to laboratory biosafety and pertains to microbiology laboratories in which the physical containment of pathogenic organisms or agents is required, usually by isolation in environmentally and biologically secure cabinets or rooms, to prevent accidental infection of workers or release into the surrounding community during scientific research.

<span class="mw-page-title-main">Biomedical Advanced Research and Development Authority</span> Government organization in Washington D.C., United States

The Biomedical Advanced Research and Development Authority (BARDA)' is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.

The National Institute for Biological Standards and Control (NIBSC) is a government agency that works in the field of biological standardisation and is part of the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA). It is responsible for developing and producing over 90% of the biological international standards in use around the world.

The Center for Infectious Disease Research and Policy (CIDRAP) is a center within the University of Minnesota that focuses on addressing public health preparedness and emerging infectious disease response. It was founded in 2001 by Dr. Michael Osterholm, in order to "prevent illness and death from infectious diseases through epidemiological research and rapid translation of scientific information into real-world practical applications and solutions". It is not part of the Center for Disease Control or National Institute of Health.

<span class="mw-page-title-main">Biomedical sciences</span> Application of science to healthcare

Biomedical sciences are a set of sciences applying portions of natural science or formal science, or both, to develop knowledge, interventions, or technology that are of use in healthcare or public health. Such disciplines as medical microbiology, clinical virology, clinical epidemiology, genetic epidemiology, and biomedical engineering are medical sciences. In explaining physiological mechanisms operating in pathological processes, however, pathophysiology can be regarded as basic science.

<span class="mw-page-title-main">Public Health England</span> Executive agency in UK health system

Public Health England (PHE) was an executive agency of the Department of Health and Social Care in England which began operating on 1 April 2013 to protect and improve health and wellbeing and reduce health inequalities. Its formation came as a result of the reorganisation of the National Health Service (NHS) in England outlined in the Health and Social Care Act 2012. It took on the role of the Health Protection Agency, the National Treatment Agency for Substance Misuse and a number of other health bodies. It was an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy.

The United States biological defense program—in recent years also called the National Biodefense Strategy—refers to the collective effort by all levels of government, along with private enterprise and other stakeholders, in the United States to carry out biodefense activities.

Translational Health Science and Technology Institute (THSTI) is a society registered under the Societies Registration Act XXI of 1860. It is also an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology, Government of India. It was set up in 2009 at Gurgaon and is now located in NCR Biotech Science Cluster, Faridabad along with the Regional Center for Biotechnology, Advanced Technology Platforms Center, Small Animal Facility, and Bio-incubator. Envisioned by former secretary of DBT, M. K. Bhan, the centre was created to enable faster transition of lab research to market. Pramod Garg is the executive director of THSTI.

The Health Protection Surveillance Centre (HPSC) is part of Ireland's Health Service Executive.

<span class="mw-page-title-main">Korea Disease Control and Prevention Agency</span> South Korean government public health agency

Korea Disease Control and Prevention Agency, formerly Korea Centers for Disease Control and Prevention, is an organization under the South Korean Ministry of Welfare and Health that is responsible for the advancement of public health by managing prevention, survey, quarantine, trial, and research on infectious diseases, chronic and rare illnesses and injuries. It was founded in December 2003 and is located in Osong Health Technology Administration Complex in Cheongju. The organization is led by the vice-ministerial-level Commissioner of KDCA.

<span class="mw-page-title-main">Chikwe Ihekweazu</span> Nigerian epidemiologist

Chikwe Ihekweazu is a Nigerian epidemiologist, public health physician and the World Health Organization’s Assistant Director-General for Health Emergency Intelligence and Surveillance Systems.

An occupational infectious disease is an infectious disease that is contracted at the workplace. Biological hazards (biohazards) include infectious microorganisms such as viruses, bacteria and toxins produced by those organisms such as anthrax.

References

  1. The Health Protection Agency Act 2004, section 1(1)
  2. "Health Protection Agency".
  3. "Anthrax vaccine". Archived from the original on 24 September 2006.
  4. "GOVERNANCE AND MANAGEMENT COMMENTARY 2008". Archived from the original on 11 March 2009. Retrieved 14 July 2009.